Bioavailability Clinical Development In-Vivo Manufacturing 
Pharmaceutical Technology
MAY 31, 2023
It is expected to accelerate the development of CFT8919 in important international markets. CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC).
Pharmaceutical Technology
FEBRUARY 13, 2023
The continued high level of interest in small molecules presents multiple opportunities to select a candidate that is ‘developable’, with subsequent rapid progression toward first-in-human (FIH) clinical testing. We start by using in-silico modeling of any pre-existing data associated with the lead compounds.
Expert insights. Personalized for you.
130 
Let's personalize your content